Thirty-three percent of cancer survivors died from cardiovascular disease, while 51% died from cancer, according to 2012 National Health and Nutrition Examination Surveys data presented by Dr. Ronald Schwartz of the University of Rochester Medical Center at the SNMMI Annual Meeting. The findings should prompt inclusion of patient-centered cardio-oncology using nuclear cardiology and radionuclide studies as well as PET/CT in comprehensive cancer care, experts said.
Researchers who analyzed data on 149 oncology patients found 36 potentially clinically important drug-to-drug interactions in 26 of them, all requiring modification of therapy, and 2.7% of patients were experiencing adverse drug reactions. The study in the Journal of Oncology Practice showed over half of patients had used herbal supplements, and researchers found 122 possible herb-to-drug interactions.
A study in the Journal of Gastroenterology and Hepatology found a modified colorectal cancer screening tool that included body mass index led to improved risk prediction for advanced neoplasia. Researchers based the tool on the Asia Pacific Colorectal Screening score.
An American Heart Association advisory published in the journal Circulation said a review of study data strongly indicates that lowering saturated fat consumption and replacing it with unsaturated fats will reduce cardiovascular disease. The advisory noted that some studies have disagreed about the adverse cardiovascular effects of saturated fat, and the issue has been hotly debated, so lead author Dr. Frank Sacks said the AHA wanted to clarify that research "overwhelmingly supports limiting saturated fat in the diet to prevent diseases of the heart and blood vessels."
Roche Holding's Kadcyla, or trastuzumab emtansine, has been recommended by the National Institute of Health and Care Excellence for use in women patients with advanced HER2-positive breast cancer that is inoperable even after treatment with Herceptin and a taxane, separately or together. The drug, which has been shown to extend lives of patients with terminal cancer by up to nine months, had previously been rejected by NICE as being too expensive.
The National Institute for Health and Care Excellence has recommended use of Takeda's Adcetris, or brentuximab vedotin, as a treatment for adult patients with CD30-positive Hodgkin lymphoma who have relapsed or refractory disease following autologous stem cell transplant. Funding via the Cancer Drugs Fund was also backed by NICE for adult patients with CD30+ve R/R Hodgkin lymphoma who have had at least two previous therapies and for whom ASCT or multiagent chemotherapy are not treatment options.
Dr. Nancy Schoenborn of Johns Hopkins University, who led a study assessing the views of older adults on stopping cancer screenings due to limited life expectancy, said patients indicated they would not think less of their physician for making such a recommendation, even if they disagreed with it. Schoenborn said some adults responded better when the conversation was structured around their health status instead of life expectancy.
Seven state governors, including three moderate Republicans, co-authored a letter to Senate Majority Leader Mitch McConnell, R-Ky., and Minority Leader Chuck Schumer, D-N.Y., stating opposition to the American Health Care Act and asking the Senate to consider bipartisan solutions to challenges seen under the Affordable Care Act. The letter emphasized the importance of stabilizing insurance markets and ensuring that states have flexibility and options to extend affordable coverage to residents, citing Medicaid cuts as a specific area of concern.
Prescription drug monitoring programs must be integrated into electronic health record systems for these programs to be of clinical value, according to a report conducted by the University of Pennsylvania and sponsored by the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV and HIV. Researchers found that PDMPs were effective in addressing the opioid crisis in the US, with states seeing a reduction in prescription opioid-related deaths of 1.12 per 100,000 people a year after its implementation.
The SNMMI-TS Publications Committee's second installment in a series of books dedicated to a single nuclear medicine procedure or imaging category -- Abdominal Imaging 2017: Quality, Safety, and Dose Optimization -- is now available. Each chapter covers imaging rationale, indications, contraindications, patient preparation and education, imaging procedure, processing, interpretation including normal and abnormal results, sensitivity/specificity/accuracy and artifacts. Pick up your copy today.
SNMMI-TS members, join Lynne Roy on July 27 at 3 p.m. ET for the complimentary webinar "The Importance of Advocacy to the Nuclear Medicine Professional." This webinar will inform you about the activities of the SNMMI's Health Policy and Regulatory Affairs Committee, focus on the importance of getting involved in technologist advocacy and create a better understanding of the factors that affect the nuclear medicine profession. Join today.
Only someone who is well-prepared has the opportunity to improvise.
Ingmar Bergman, director and screenwriter
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at firstname.lastname@example.org.